3.665
4.45%
-0.155
시간 외 거래:
3.67
0.005
+0.14%
전일 마감가:
$3.82
열려 있는:
$3.82
하루 거래량:
877.48K
Relative Volume:
0.66
시가총액:
$306.23M
수익:
$7.05M
순이익/손실:
$-30.43M
주가수익비율:
-4.998
EPS:
-0.7333
순현금흐름:
$21.84M
1주 성능:
-7.83%
1개월 성능:
-15.70%
6개월 성능:
+88.14%
1년 성능:
+148.30%
Proqr Therapeutics N V Stock (PRQR) Company Profile
PRQR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
PRQR | 3.665 | 306.23M | 7.05M | -30.43M | 21.84M | -0.7333 |
VRTX | 467.12 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.38 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
2022-02-01 | 개시 | Raymond James | Strong Buy |
2021-05-03 | 개시 | Stifel | Buy |
2021-03-25 | 재확인 | Citigroup | Buy |
2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
2018-11-15 | 개시 | Citigroup | Buy |
2018-09-19 | 개시 | Evercore ISI | Outperform |
2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
2014-10-15 | 개시 | Deutsche Bank | Buy |
2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com
Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World
What is Chardan Capital's Forecast for PRQR FY2024 Earnings? - MarketBeat
ProQR: Q3 Earnings Snapshot - San Francisco Chronicle
ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
ProQR Therapeutics NV earnings beat, revenue fell short of estimates - Investing.com
ProQR Therapeutics NV earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
PRQRProQR Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
ProQR Announces Third Quarter 2024 Operating and Financial Results - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN
ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire
ProQR Announces Major Share Offering Agreement - TipRanks
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump - Simply Wall St
ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in - XM
Form 424B5 ProQR Therapeutics N.V. - StreetInsider.com
ProQR launches public offering to fund RNA therapy research - Investing.com India
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - StockTitan
ProQR Therapeutics announces public offering of ordinary shares - MSN
ProQR launches public offering to fund RNA therapy research By Investing.com - Investing.com UK
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance
RNA-Editing Stocks Soar by Record on Wave Life’s Trial Data - Yahoo Finance
Proqr Therapeutics RNA editing technology counteracts cholestatic disease - BioWorld Online
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewswire Inc.
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Investing in ProQR Therapeutics N.V (PRQR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Best Momentum Stocks to Buy for October 2nd - Yahoo Finance
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase By Investing.com - Investing.com South Africa
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $1.95 - Defense World
ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - SETE News
What technical indicators reveal about PRQR stock - US Post News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Yahoo Finance UK
ProQR Therapeutics NV (FRA:0PQ) Financial Strength : 3 (As of Jun. 2024) - GuruFocus.com
Reviewing ProQR Therapeutics (NASDAQ:PRQR) and OptiNose (NASDAQ:OPTN) - Defense World
ProQR Therapeutics NV (FRA:0PQ) Enterprise Value : €86.81 Mil (As of Aug. 17, 2024) - GuruFocus.com
Comparing Moleculin Biotech (NASDAQ:MBRX) & ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):